Peter G. Traber, M.D., CEO & CMO of Galectin Therapeutics, to Speak on the Medical Applications of Plant-Derived Complex Carb...
July 13 2016 - 8:56AM
Business Wire
Dr. Traber to speak on Galectin Therapeutics’
Development of GR-MD-02 for treatment of human disease
Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading
developer of therapeutics that target galectin proteins to treat
fibrosis and cancer, today announced that Peter G. Traber, M.D.,
chief executive officer and chief medical officer, has been invited
to speak at the 10th Georgia Glycoscience Symposium and 2016 Plant
Polysaccharide Workshop to be held at the Complex Carbohydrate
Research Center at the University of Georgia on July 14 and 15.
Dr. Traber will speak on the “Use of Plant-Derived Complex
Carbohydrates for Disease Treatment,” outlining Galectin
Therapeutics’ development of GR-MD-02, a compound derived from a
plant-based complex carbohydrate called pectin. GR-MD-02 is
currently in two Phase 2 clinical trials in subjects with
non-alcoholic steatohepatitis (NASH) with cirrhosis and NASH with
advanced fibrosis, as well as in preclinical testing for lung,
kidney and cardiovascular fibrosis. GR-MD-02 is also being studied
in two clinical trials at Providence Portland Medical Center in
advanced melanoma patients in combination with Keytruda® and
Yervoy®, as well as in a Phase 2a trial in patients with
moderate-to-severe plaque psoriasis.
“For many years, plant-derived compounds have been used as drugs
for the treatment of many human diseases.” said Dr. Traber. “Our
novel drug candidate, GR-MD-02, is derived from complex
carbohydrates, which are long chains of sugar molecules, and
represents a new class of plant-derived drugs that may have
important medical applications in a broad range of disease.”
About GR-MD-02
GR-MD-02 is a complex carbohydrate drug that targets galectin-3,
a critical protein in the pathogenesis of fatty liver disease and
fibrosis. Galectin-3 plays a major role in diseases that involve
scarring of organs including fibrotic disorders of the liver, lung,
kidney, heart and vascular system. The drug binds to galectin
proteins and disrupts their function. Preclinical data in animals
have shown that GR-MD-02 has robust treatment effects in reversing
liver fibrosis and cirrhosis.
About Fatty Liver Disease with Advanced Fibrosis and
Cirrhosis
Non-alcoholic steatohepatitis (NASH), also known as fatty liver
disease, has become a common disease of the liver with the rise in
obesity rates. NASH is estimated to affect up to 28 million people
in the U.S. Fatty liver disease is characterized by the presence of
fat in the liver along with inflammation and damage in people who
consume little or no alcohol. Over time, patients with fatty liver
disease can develop fibrosis, or scarring of the liver, and it is
estimated that as many as 1-2 million individuals in the U.S. have
cirrhosis, a severe liver disease for which liver transplant is the
only treatment available. Approximately 6,300 liver transplants are
performed annually in the U.S. There are no drug therapies approved
for the treatment of NASH or liver fibrosis. A recent analyst
estimate indicated that by 2025 the worldwide market for NASH
treatments could approach $35 billion.
About Galectin Therapeutics
Galectin Therapeutics is developing promising therapies for the
treatment of fibrotic liver disease and cancer based on the
Company's unique understanding of galectin proteins, which are key
mediators of biologic function. Galectin seeks to leverage
extensive scientific and development expertise as well as
established relationships with external sources to achieve
cost-effective and efficient development. The Company is pursuing a
development pathway to clinical enhancement and commercialization
for its lead compounds in liver fibrosis, psoriasis and cancer.
Additional information is available at
www.galectintherapeutics.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements relate to future events or future financial
performance, and use words such as “may,” “estimate,” “could,”
“expect” and others. They are based on management’s current
expectations and are subject to factors and uncertainties that
could cause actual results to differ materially from those
described in the statements. These statements include those
regarding the hope that its lead compounds will be successful in
treating fibrosis, cancer and psoriasis. Regardless of the results
of any of its development programs, Galectin may be unsuccessful in
developing partnerships with other companies or raising additional
capital that would allow it to further develop and/or fund any
studies or trials. For a discussion of additional factors impacting
Galectin’s business, see the Company’s Annual Report on Form 10-K
for the year ended December 31, 2015, and subsequent filings with
the SEC. You should not place undue reliance on forward-looking
statements.
Although subsequent events may cause its views to change,
management disclaims any obligation to update forward-looking
statements.
Galectin Therapeutics and its associated logo is a registered
trademark of Galectin Therapeutics Inc.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160713005262/en/
Galectin Therapeutics, Inc.Jack Callicutt, Chief Financial
Officer678-620-3186ir@galectintherapeutics.comorGregory FCAJoe
Hassett, Senior Vice President610-228-2110joeh@gregoryfca.com
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Sep 2023 to Sep 2024